View in EDS

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.

Saved in:
Bibliographic Details
Title: Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.
Authors: Raychaudhuri S; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Gooley TA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Rasmussen A; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Quach K; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Gill E; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Halpern AB; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Appelbaum JS; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Ghiuzeli CM; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Hendrie PC; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Cassaday RD; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Walter RB; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA., Percival MM; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Source: Blood neoplasia [Blood Neoplasia] 2025 Mar 03; Vol. 2 (3), pp. 100085. Date of Electronic Publication: 2025 Mar 03 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918841988906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2950-3280 (Electronic) Linking ISSN: 29503280 NLM ISO Abbreviation: Blood Neoplasia Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40535475
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Raychaudhuri+S%22">Raychaudhuri S</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Gooley+TA%22">Gooley TA</searchLink>; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Rasmussen+A%22">Rasmussen A</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Quach+K%22">Quach K</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Gill+E%22">Gill E</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Halpern+AB%22">Halpern AB</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Appelbaum+JS%22">Appelbaum JS</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Ghiuzeli+CM%22">Ghiuzeli CM</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Hendrie+PC%22">Hendrie PC</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Cassaday+RD%22">Cassaday RD</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Walter+RB%22">Walter RB</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Percival+MM%22">Percival MM</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918841988906676%22">Blood neoplasia</searchLink> [Blood Neoplasia] 2025 Mar 03; Vol. 2 (3), pp. 100085. <i>Date of Electronic Publication: </i>2025 Mar 03 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%2C+Inc%22">Elsevier, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918841988906676 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2950-3280 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2229503280%22">29503280 </searchLink><i>NLM ISO Abbreviation: </i>Blood Neoplasia <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40535475
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.bneo.2025.100085
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100085
    Titles:
      – TitleFull: Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Raychaudhuri S
      – PersonEntity:
          Name:
            NameFull: Gooley TA
      – PersonEntity:
          Name:
            NameFull: Rasmussen A
      – PersonEntity:
          Name:
            NameFull: Quach K
      – PersonEntity:
          Name:
            NameFull: Gill E
      – PersonEntity:
          Name:
            NameFull: Halpern AB
      – PersonEntity:
          Name:
            NameFull: Appelbaum JS
      – PersonEntity:
          Name:
            NameFull: Ghiuzeli CM
      – PersonEntity:
          Name:
            NameFull: Hendrie PC
      – PersonEntity:
          Name:
            NameFull: Cassaday RD
      – PersonEntity:
          Name:
            NameFull: Walter RB
      – PersonEntity:
          Name:
            NameFull: Percival MM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 03
              M: 03
              Text: 2025 Mar 03
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2950-3280
          Numbering:
            – Type: volume
              Value: 2
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Blood neoplasia
              Type: main
ResultId 1